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Purpose. Imatinib treatment causes muscle cramps in up to 40% of patients, but their pathogenesis is unknown. We present a case
series illustrating an association between imatinib, relative hypocalcaemia, and the development of cramps. Patients. The index
patient developed muscle spasms and cramps after receiving imatinib for gastrointestinal stromal tumour (GIST) for 5 months.
The adjusted serum calcium had dropped to the lower limit of normal. The low serum calcium and muscle cramps improved
on stopping imatinib and recurred on rechallenge. We reviewed the medical records of 16 further patients. Results. Two patients
reported muscle cramps (12%). There was a rapid and sustained reduction in adjusted serum calcium in the first 6 months from
2.45 ± 0.11mmol/L (mean ± SD) to 2.30 ± 0.08mmol/L (p = 0.025). Conclusion. Imatinib treatment of GIST is associated with
reduction in serum calcium which may explain the development of neuromuscular symptoms. In patients receiving imatinib,
serum electrolytes should bemonitored andmuscle cramps treated by correction of serum calcium, or an empirical trial of quinine
sulphate.
Copyright © 2006 Jamal M. Zekri et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Imatinib mesylate is a tyrosine kinase inhibitor targeted to
BCR-ABL, PDGFR, and KIT. It has unprecedented activity
in chronic myelogenous leukaemia (CML) and gastrointesti-
nal stromal tumours (GISTs), and has dramatically changed
the clinical management of these tumour types [1–4]. GISTs
characteristically have an activating mutation in the KIT re-
ceptor. Objective response rates to imatinib in GIST are just
over 50% [5, 6]. Recent data suggest that the presence of
exon 11 mutations in KIT predict for response to imatinib,
with a response rate of 83% in this patient group [7]. In pa-
tients with advanced GIST, imatinib treatment has improved
median survival from less than 1 year to more than 3 years,
with 65% of patients free of progression and 85% alive at one
year [6]. Imatinib is administered by mouth as a daily dose
of 400–800mg until tumour progression.
The adverse eﬀects of imatinib are mostly mild and man-
ageable. The most common adverse eﬀects reported by GIST
patients are listed in Table 1. Musculoskeletal eﬀects of ima-
tinib are reported in 25% of GIST patients and 20–40%
of CML patients, including arthralgia, myalgia, and muscle
cramps, but are rarely dose-limiting [2, 5, 6, 8]. The patho-
physiology of these eﬀects is uncertain. Here, we report a pa-
tient in whom the development of cramps and involuntary
movements while receiving imatinib was associated with a
significant reduction in adjusted serum calcium levels. We
then studied the calcium level changes in a cohort of pa-
tients receiving imatinib for GIST and found that reduction
in serum calcium occurred in all.
CASE REPORT
A 38-year-old woman with extensive abdominal GIST com-
menced imatinib mesylate (Glivec, Novartis) 400mg/day in
October 2003. Her adjusted serum calcium was 2.54mmol/L
(normal range 2.2–2.55). Imatinib was well tolerated, and
her tumour mass slowly responded to treatment. She was ac-
tive (performance status 1), had a normal diet and no evi-
dence of malabsorption. During the fifth month of therapy,
she complained of increasing muscle twitches and cramps,
locked fingers, and spasm of the tongue. Her adjusted serum
calcium was 2.28 and magnesium 0.75 (0.7–0.95)mmol/L,
both at the lower limit of the normal ranges.
On stopping imatinib, the symptoms rapidly resolved,
and the serum calcium andmagnesium recovered to 2.37 and
1.0mmol/L respectively (Figure 1). Imatinib was restarted
after 3 weeks, with oral calcium and magnesium supple-
ments, but the cramps recurred. She was then given qui-
nine sulphate 300mg/day, with complete resolution of the
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Table 1: Incidence of common adverse eﬀects (%) in patients re-
ceiving imatinib 400mg/day for GIST, among 470 patients in a ran-
domised clinical trial (from Verweij et al [6]).
Adverse eﬀect Grades 1/2 Grades 3/4
Anaemia 82 7
Oedema 69 3
Fatigue 62 6
Pleuritic pain 47 4
Nausea 46 2.5
Diarrhea 46 1.7
Cramps 37 1.3
Granulocytopenia 34 7
Rash 24 2.3
Myalgia 24 0.2
Arthralgia 13 0
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Figure 1: Changes in adjusted serum calcium in the index pa-
tient from the start of imatinib treatment. Reference range 2.2–
2.55mmol/L.
cramps. Fifteen months later, she continues on imatinib
400mg/day with quinine sulphate 300mg/day. The tumour
mass continues to regress. Her serum calcium remains at the
lower limit of the normal range, but her cramps are con-
trolled with quinine sulphate.
REVIEW OF CASE SERIES
In view of the findings in this patient, we undertook to re-
view the medical notes of a cohort of 17 consecutive pa-
tients treated in our institution with imatinib for GIST. We
noted the occurrence of musculoskeletal adverse eﬀects and
recorded adjusted serum calcium levels. Magnesium levels
had not been consistently assessed and hence are not avail-
able for this report. Results are expressed as mean± standard
deviation, and two-tailed paired t tests were used to test the
diﬀerence in means.
The characteristics of the 17 patients are shown in Ta-
ble 2. These are comparable to those in reported trial se-
ries. All had inoperable, locally advanced or metastatic KIT-
Table 2: Patient characteristics.
Age (years) Median 60, range 38–83
Sex Male 7, female 10
Starting dose of imatinib
400mg, 12 patients
800mg, 5 patients
Duration of treatment, months Median 23, range 3–39
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Figure 2: Changes in adjusted serum calcium in 17 patients receiv-
ing imatinib for advanced GIST, shown as mean ± standard devia-
tion. Reference range 2.2–2.55mmol/L.
positive GIST. None was receiving bisphosphonates. The
median progression-free and overall survival had not been
reached at time of analysis. In addition to the index patient,
only one other reported symptoms of involuntary move-
ments and cramps. These did not lead to imatinib dose re-
duction or withdrawal, but were managed with quinine sul-
phate 300mg prn.
At the start of imatinib treatment, all patients had nor-
mal serum calcium levels (mean 2.45 ± SD 0.11mmol/L).
All patients exhibited a rapid and sustained fall in adjusted
serum calcium during treatment with imatinib to 2.30 ±
0.08mmol/L at 6 months (Figure 2) although few readings
were below the lower limit of the normal range. The reduc-
tion in adjusted serum calcium was statistically significant at
each time point from week 2 to month 6 (P = 0.002–0.05).
DISCUSSION
The appearance of neuromuscular symptoms in the index
patient after 4 months of imatinib, their resolution on stop-
ping the drug and reappearance on restarting it are highly
suggestive of a causal eﬀect of imatinib. As muscle cramps
occur in up to 40% of patients on receiving imatinib, this was
not an unexpected finding [2, 5, 6, 8]. However, the clear as-
sociation with adjusted serum calcium levels, seen here, sug-
gested that the reduced calcium level was also an eﬀect of
imatinib treatment, and possibly associated with the mus-
cle cramps. To explore this association further, we studied a
further 16 patients receiving imatinib for GIST. Interestingly,
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we found that imatinib treatment is consistently associated
with a rapid and sustained fall in adjusted serum calcium,
albeit usually within the normal reference range. We there-
fore hypothesise that imatinib treatment is associated with
relative hypocalcaemia that can precipitate neuromuscular
symptoms in some patients.
Muscle cramps and other neuromuscular or symptoms
have been widely reported in patients receiving imatinib.
They usually occur in the hands, feet, calves, and thighs,
and may be tetanic in nature [2]. The cramps tend not to
change over time with respect to pattern, frequency, and
severity. They do tend to have consistent triggers, and some
patients report experiencing them mainly at night or with
exertion. Although such patients do not typically have lev-
els of ionized calcium or magnesium below the lower limit
of normal, some benefit from calcium and magnesium sup-
plements [2, 9]. Oral fluids have been encouraged, and qui-
nine sulphate has been used empirically, with improvement
in some patients. Recent data suggest that GIST can progress
rapidly when imatinib is discontinued [10], so this cannot be
recommended as a strategy for dealing with cramps unless
they are extremely severe.
Interestingly, a reduction in the serum calcium has pre-
viously been noted in patients receiving imatinib for CML,
but is not widely recognised. Steegmann et al [11] found
significant reductions in serum calcium and phosphate in
the patients receiving the imatinib for interferon-resistant
or -intolerant CML, but no change in serum creatinine or
creatinine clearance. There was no association with neuro-
muscular symptoms in this study. The failure to observe an
association between imatinib and relative hypocalcaemia in
other large series is probably because the changes are typi-
cally within the normal reference range. The high reported
incidence of muscle cramps however suggests that relative
hypocalcaemia may be a common problem in these patients.
The pathophysiological basis for this association remains
uncertain but some possibilities can be considered. Firstly,
although KIT is expressed on renal tubular cells, their func-
tions there are unknown. Imatinib could therefore be exert-
ing a direct eﬀect on renal tubular KIT receptors, resulting in
relative hypocalcaemia. Secondly, imatinib is a member of a
family of protein tyrosine kinase inhibitors which can induce
marked changes in cell excitability and ion homeostasis. In-
deed, imatinib blocks low voltage-activated T-type calcium
channels in human embryonic kidney cells [12]. Thus ima-
tinib could have a nonspecific eﬀect on calcium homeostatsis
that is not KIT receptor-mediated.
Our findings suggest that imatinib treatment in GIST pa-
tients is commonly associated with relative hypocalcaemia,
which may contribute to the occurrence of neuromuscular
symptoms in up to 40% of patients. The adjusted serum cal-
cium rarely falls below the lower limit of normal. It may
be prolonged, but it is not cumulative. We recommend that
serum electrolytes should be monitored in these patients, so
that symptomatic hypocalcaemia can be corrected. In the
presence of muscle cramps, electrolyte replacement or qui-
nine sulphate can be tried. Imatinib should not be discontin-
ued unless the cramps are very severe.
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